A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study-Reference-Cited by-同舟云学术

A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study

Published:2023-02-19 Issue:1 Volume:28 Page:
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Ríos-Tamayo Rafael¹,Soler Juan Alfons²,García-Sánchez Ricarda³,Pérez Persona Ernesto⁴,Arnao Mario⁵,García-Guiñón Antoni⁶,Domingo Abel⁷,González-Pardo Miriam⁸^ORCID,de la Rubia Javier⁹¹⁰¹¹,Mateos María Victoria¹²,

Affiliation:

1. Department of Hematology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain

2. Department of Hematology, Hospital Universitari Parc Taulí de Sabadell, Catalonia, Spain

3. Department of Hematology, Hospital Virgen de la Victoria, Málaga, Spain

4. Department of Hematology, Hospital Universitario de Navarra, Pamplona, Spain

5. Department of Hematology, Hospital Universitari i Politècnic La Fe, Valencia, Spain

6. Department of Hematology, Hospital Universitari Arnau de Vilanova, Lleida, Spain

7. Department of Hematology, Hospital General de Granollers, Spain

8. Medical Department, Janssen-Cilag España, Spain

9. Hospital Universitari i Politècnic La Fe, Valencia, Spain

10. Hematology Department, Universidad Católica “San Vicente Mártir”, Valencia, Spain

11. CIBERONC CB16/12/00284, Valencia, Spain

12. Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Hospital Universitario de Salamanca, Salamanca, Spain

Funder

Janssen-Cilag

Publisher

Informa UK Limited

Subject

Hematology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2023.2178997

Reference55 articles.

1. Multiple myeloma epidemiology and survival: A unique malignancy

2. Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study

3. Novel Therapies in the Treatment of Multiple Myeloma

4. Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials

5. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world treatment patterns in patients initiating third‐line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain;European Journal of Haematology;2023-12-25